inclusion criteria: * male or female patients, age 18 years or older on the day of signing the informed consent form. * agrees to admission to an in-patient facility for monitoring from days 1 to 8, inclusive. * symptoms of mild illness with covid-19 without shortness of breath, dyspnea, or clinical signs indicative of more serious covid-19. * laboratory confirmed sars-cov-2 infection within 4 days prior to the screening visit or during the 7-day screening period. * respiratory rate \< 20 breaths per minute, heart rate \< 90 beats per minute (bpm). * oxygen saturation by pulse oximetry \> 93% on room air. * body mass index \< 35 kg/m2. * estimated glomerular filtration rate (egfr) ≥ 30 ml/min. * alanine transaminase (alt) or aspartate transaminase (ast) \< 2 x upper limit of normal (uln) and total bilirubin \< 1.5 x uln. * agrees to not participate in another clinical trial for the treatment of covid-19 while on study unless the patient's condition has worsened and is considered to be moderate, severe, or critical by the investigator.

inclusion criteria: * male or female patients, age 18 years or older on the day of signing the informed consent form. * agrees to admission to an in-patient facility for monitoring from days 1 to 8, inclusive. * symptoms of mild illness with covid-19 without shortness of breath, dyspnea, or clinical signs indicative of more serious covid-19. * laboratory confirmed sars-cov-2 infection within 4 days prior to the screening visit or during the 7-day screening period. * respiratory rate \< 20 breaths per minute, heart rate \< 90 beats per minute (bpm). * oxygen saturation by pulse oximetry \> 93% on room air. * body mass index \< 35 kg/m2. * estimated glomerular filtration rate (egfr) ≥ 30 ml/min. * alanine transaminase (alt) or aspartate transaminase (ast) \< 2 x upper limit of normal (uln) and total bilirubin \< 1.5 x uln. * agrees to not participate in another clinical trial for the treatment of covid-19 while on study unless the patient's condition has worsened and is considered to be moderate, severe, or critical by the investigator.

inclusion criteria: - male or female patients, age 18 years or older on the day of signing the informed consent form. - agrees to admission to an in-patient facility for monitoring from days 1 to 8, inclusive. - symptoms of mild illness with covid-19 without shortness of breath, dyspnea, or clinical signs indicative of more serious covid-19. - laboratory confirmed sars-cov-2 infection within 4 days prior to the screening visit or during the 7-day screening period. - respiratory rate < 20 breaths per minute, heart rate < 90 beats per minute (bpm). - oxygen saturation by pulse oximetry > 93% on room air. - body mass index < 35 kg/m2. - estimated glomerular filtration rate (egfr) ≥ 30 ml/min. - alanine transaminase (alt) or aspartate transaminase (ast) < 2 x upper limit of normal (uln) and total bilirubin < 1.5 x uln. - agrees to not participate in another clinical trial for the treatment of covid-19 while on study unless the patient's condition has worsened and is considered to be moderate, severe, or critical by the investigator.

inclusion criteria: - male or female patients, age 18 years or older on the day of signing the informed consent form. - agrees to admission to an in-patient facility for monitoring from days 1 to 8, inclusive. - symptoms of mild illness with covid-19 without shortness of breath, dyspnea, or clinical signs indicative of more serious covid-19. - laboratory confirmed sars-cov-2 infection within 4 days prior to the screening visit or during the 7-day screening period. - respiratory rate < 20 breaths per minute, heart rate < 90 beats per minute (bpm). - oxygen saturation by pulse oximetry > 93% on room air. - body mass index < 35 kg/m2. - estimated glomerular filtration rate (egfr) ≥ 30 ml/min. - alanine transaminase (alt) or aspartate transaminase (ast) < 2 x upper limit of normal (uln) and total bilirubin < 1.5 x uln. - agrees to not participate in another clinical trial for the treatment of covid-19 while on study unless the patient's condition has worsened and is considered to be moderate, severe, or critical by the investigator.